ArticleOdontology2026
Injectable GSK3 inhibitor (Tideglusib) hydrogel versus enhanced β-tricalcium phosphate in tibial bone healing (in vitro and in vivo study).
Article in Odontology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study was carried out to assess the potential effect of a glycogen synthase kinase-3 inhibitor tideglusib hydrogel formulation on bone regeneration and to compare it with Ethoss a beta tricalcium phosphate alloplastic bone substitute mixed with calcium sulphate in vitro and in vivo. Bone marrow mesenchymal stem cells (BMMSCs) were isolated from New Zealand white rabbit tibias and characterized by flowcytometric analysis. Sodium alginate hydrogel loaded with tideglusib was formulated and underwent characterization by scanning electron microscopy, the fourier transform infrared and zeta potential. Extraction media from both tideglusib hydrogel and Ethoss were prepared then MTT, alizarin red (ARS) and scratch wound assays were performed. Two bone defects were trephined in tibias of eighteen adult healthy rabbits, which were classified into three groups: group 1, bone defects were left untreated; group 2, each defect was filled with tideglusib hydrogel; group 3, each defect was filled with Ethoss. Animals were sacrificed after three and six weeks. Histological and immunohistochemical analyses using alkaline phosphatase (ALP) and osteopontin (OPN) were performed to assess bone regeneration. The tideglusib hydrogel group expressed higher mineral deposition than Ethoss group using ARS but without significant difference, stronger stimulatory effect on the migration of BMMSCs was also evident with significant narrowing of the wound area. New bone tissue was progressively seen bridging and filling the defects with significantly higher ALP and OPN expression in hydrogel group. Tideglusib hydrogel formulation exhibited superior bone regenerative potential in comparison to beta tricalcium phosphate alloplastic bone substitute.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.